首頁 > 市場調查報告書 > 製藥

精神疾病

市場調查報告書

商品編碼

1123047

憂鬱症治療藥的全球市場:2022-2028年

Global Depression Treatment Therapy Market Research and Forecast, 2022-2028

出版日期: 2022年07月13日 | 出版商:

Orion Market Research | 英文 145 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

全球憂鬱症治療藥的市場規模，從2020年到2027年的預測期間內預計以4.1％的年複合成長率大幅成長。

在世界憂鬱症的盛行率上升，促進該市場的成長。還有精神疾病的認識高漲，及憂鬱症罹患率高的老年人口增加也成為加速市場成長的要素之一。

本報告提供全球憂鬱症治療藥的市場調查，市場概要，市場成長的各種影響因素分析，市場規模的變化、預測，各種區分、各地區/主要國家的明細，競爭環境，主要企業簡介等彙整資訊。

Alkermes Plc
Allergen Plc
AstraZeneca plc
Bausch Health Companies, Inc.
Eli Lilly and Co.
F. Hoffmann-La Roche AG
Garmin Ltd.
GlaxoSmithKline plc
H. Lundbeck A/S
Johnson & Johnson Services, Inc.
Lief Therapeutics
Lupin Ltd.
MagVenture, Inc.
Mylan N.V.
Novartis AG
Otsuka Pharmaceutical Co., Ltd.
Pfizer, Inc.
Sanofi SA
Takeda Pharmaceutical Co. Ltd.
Teva Pharmaceutical Industries Ltd.

簡介目錄圖表

Product Code: PHM-1302

Global Depression Treatment Market Size, Share & Trends Analysis Report by Drug Type (Selective Serotonin Reuptake Inhibitors, Tricyclic Antidepressants, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, and Others) Forecast Period 2020-2027

The global depression treatment market is anticipated to grow at a considerable CAGR of 4.1% during the forecast period of 2020-2027. Depression treatments are the type of prescription given to alleviate the symptoms of anxiety disorders, mild chronic depression, and Major Depressive Disorder (MDD). The rising prevalence of depression among the global population is the major factor driving the growth of the depression treatment market.

Besides, the increasing awareness about mental illness, and the growing geriatric population with a higher rate of depression, is another factor accelerating the market growth. According to the report of the World Health Organization (WHO) published in January 2020, there are around 800,000 suicide-related mortalities every year, and 264 million people of all ages suffer from depression globally.

Moreover, depression is the second leading cause of suicide in the young generation which is expected to increase due to change in lifestyle and increasing workload. The presence of depression disorder cases is higher in the US. According to the estimates of Anxiety and Depression Foundation facts and statistics, 6.8 million adults, or 3.1% of the US population have been affected by a generalized anxiety disorder. In line with this, 6 million adults, or 2.7% of the US population are affected by panic disorder. Other factors such as chronic medical conditions, crimes such as sexual abuse, femicide along other behavioral issues may further lead to depression, which in turn, creates demand for depression treatment drugs.

Segmental Outlook

The global depression treatment market is segmented on the basis of drug type into selective serotonin reuptake inhibitors, tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, and others.

Selective Serotonin Reuptake Inhibitors (SSRIs) in Drug Type Segment Hold Significant Share

The Selective Serotonin reuptake inhibitors (SSRI) segment is anticipated to grow at a significant pace during the forecast period. The SSRI is a type of drug used to treat mental illnesses such as depression and anxiety disorder by elevating the extracellular levels of serotonin. Selective serotonin reuptake inhibitors are widely used across the globe as they are highly effective in the treatment of depression. These are the most commonly prescribed antidepressant drugs, as it possesses maximum benefits with fewer side effects as compared to other drugs. Similar to other antidepressants, certain SSRIs are prescribed as a treatment for chronic pain conditions.

Regional Outlook

The global depression treatment market is analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. On the basis of geography, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America is estimated to be the leading region in the global depression treatment market and is expected to remain dominant during the forecast period. The factors contributing to the growth of this region include the presence of a large number of depression cases and the accessibility of antidepressants across the region. In addition, the government policies regarding drug launches and generic drug production are the major factors driving the growth of the depression treatment market. The Asia-Pacific is estimated to be the fastest-growing region in the depression treatment market during the forecast period (2021-2027).

Global Depression Treatment Market Growth, by Region 2021-2027

Global Depression Treatment Market Growth, by Region

Asia-Pacific is projected to have considerable growth in the global depression treatment market.

Asia-Pacific is projected to be the fastest-growing market during the forecast period. The factor contributing to the growth of the depression treatment market in this region includes the rising prevalence of psychiatric disorders. Besides, the development of new therapies and devices to reduce the depression rate by investing high amounts through key market players are the key factors for the market growth. Moreover, the production of new antidepressant drugs in emerging countries such as China, India, Japan, and others is anticipated to drive the depression treatment market in the region.

Market Players Outlook

Some of the key players of the depression market include Eli Lilly and Co., Johnson & Johnson, Pfizer, Inc., Merck & Co., Inc., H. Lundbeck A/S., F. Hoffmann-La Roche Ltd, and others. In order to gain a strong position in the market, these players adopt various marketing strategies such as mergers & acquisitions, R&D, product launch, and geographical expansion so on. For instance, in August 2019, Lupin, a pharmaceutical company had launched an antidepressant drug Fluoxetine Tablets USP, 10 mg and 20 mg. The company had received the US FDA approval for Prozac which is indicated for the treatment of Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Bulimia Nervosa, and Panic Disorder.

The Report Covers

Market value data analysis of 2019 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global depression treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where in the market.

1. Report Summary

1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. By Geography

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion
2.3. Regulations

3. Competitive Landscape

3.1. Key Company Analysis
- 3.1.1. Overview
- 3.1.2. Financial Analysis
- 3.1.3. SWOT Analysis
- 3.1.4. Recent Developments
3.2. Key Strategy Analysis

4. Market Determinants

4.1. Motivators
4.2. Restraints
4.3. Opportunities

5. Market Segmentation

5.1. Global Depression Treatment Market by Drugs Type
- 5.1.1. Selective Serotonin Reuptake Inhibitors
- 5.1.2. Tricyclic Antidepressants
- 5.1.3. Serotonin-Norepinephrine Reuptake Inhibitors
- 5.1.4. Monoamine Oxidase Inhibitors
- 5.1.5. Others

6. Regional Analysis

6.1. North America
- 6.1.1. United States
- 6.1.2. Canada
6.2. Europe
- 6.2.1. UK
- 6.2.2. Germany
- 6.2.3. Italy
- 6.2.4. Spain
- 6.2.5. France
- 6.2.6. Rest of Europe
6.3. Asia-Pacific
- 6.3.1. China
- 6.3.2. India
- 6.3.3. Japan
- 6.3.4. Rest of Asia-Pacific
6.4. Rest of the World

7. Company Profiles

7.1. Alkermes Plc
7.2. Allergen Plc
7.3. AstraZeneca plc
7.4. Bausch Health Companies, Inc.
7.5. Eli Lilly and Co.
7.6. F. Hoffmann-La Roche AG
7.7. Garmin Ltd.
7.8. GlaxoSmithKline plc
7.9. H. Lundbeck A/S
7.10. Johnson & Johnson Services, Inc.
7.11. Lief Therapeutics
7.12. Lupin Ltd.
7.13. MagVenture, Inc.
7.14. Mylan N.V.
7.15. Novartis AG
7.16. Otsuka Pharmaceutical Co., Ltd.
7.17. Pfizer, Inc.
7.18. Sanofi SA
7.19. Takeda Pharmaceutical Co. Ltd.
7.20. Teva Pharmaceutical Industries Ltd.

簡介目錄圖表

LIST OF TABLES

1. GLOBAL DEPRESSION TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUGS TYPE, 2019-2027 ($ MILLION)
2. GLOBAL SELECTIVE SEROTONIN REUPTAKE INHIBITORS MARKET RESEARCH AND ANALYSIS BY DRUGS REGION, 2019-2027 ($ MILLION)
3. GLOBAL TRICYCLIC ANTIDEPRESSANTS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2027 ($ MILLION)
4. GLOBAL SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2027 ($ MILLION)
5. GLOBAL MONOAMINE OXIDASE INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2027 ($ MILLION)
6. GLOBAL OTHER DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2027 ($ MILLION)
7. GLOBAL DEPRESSION TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2027 ($ MILLION)
8. NORTH AMERICAN DEPRESSION TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2027 ($ MILLION)
9. NORTH AMERICAN DEPRESSION TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2019-2027 ($ MILLION)
10. EUROPEAN DEPRESSION TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2027 ($ MILLION)
11. EUROPEAN DEPRESSION TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE,2019-2027 ($ MILLION)
12. ASIA-PACIFIC DEPRESSION TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2027 ($ MILLION)
13. ASIA-PACIFIC DEPRESSION TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE,2019-2027 ($ MILLION)
14. REST OF THE WORLD DEPRESSION TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE,2019-2027 ($ MILLION)

LIST OF FIGURES

1. GLOBAL DEPRESSION TREATMENT MARKET SIZE, 2-19-2027 ($ MILLION)
2. GLOBAL DEPRESSION TREATMENT MARKET SHARE BY DRUG TYPE, 2019 VS 2027 (%)
3. GLOBAL SELECTIVE SEROTONIN REUPTAKE INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2019 VS 2027 (%)
4. GLOBAL TRICYCLIC ANTIDEPRESSANTS MARKET RESEARCH AND ANALYSIS BY REGION, 2019 VS 2027 (%)
5. GLOBAL SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2019 VS 2027 (%)
6. GLOBAL MONOAMINE OXIDASE INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2019 VS 2027 (%)
7. GLOBAL OTHER DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2019 VS 2027 (%)
8. GLOBAL DEPRESSION TREATMENT RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019 VS 2027 (%)
9. US DEPRESSION TREATMENT MARKET SIZE, 2019-2027 ($ MILLION)
10. CANADA DEPRESSION TREATMENT MARKET SIZE, 2019-2027 ($ MILLION)
11. UK DEPRESSION TREATMENT MARKET SIZE, 2019-2027 ($ MILLION)
12. FRANCE DEPRESSION TREATMENT MARKET SIZE, 2019-2027 ($ MILLION)
13. GERMANY DEPRESSION TREATMENT MARKET SIZE, 2019-2027 ($ MILLION)
14. ITALY DEPRESSION TREATMENT MARKET SIZE, 2019-2027 ($ MILLION)
15. SPAIN DEPRESSION TREATMENT MARKET SIZE, 2019-2027 ($ MILLION)
16. REST OF EUROPE DEPRESSION TREATMENT MARKET SIZE, 2019-2027 ($ MILLION)
17. INDIA DEPRESSION TREATMENT MARKET SIZE, 2019-2027 ($ MILLION)
18. CHINA DEPRESSION TREATMENT MARKET SIZE, 2019-2027 ($ MILLION)
19. JAPAN DEPRESSION TREATMENT MARKET SIZE, 2019-2027 ($ MILLION)
20. REST OF ASIA-PACIFIC DEPRESSION TREATMENT MARKET SIZE, 2019-2027 ($ MILLION)
21. REST OF THE WORLD DEPRESSION TREATMENT MARKET SIZE, 2019-2027 ($ MILLION)